Hologic to Sell Blood-Screening Business to Grifols for USD 1.85 Billion
|
By LabMedica International staff writers Posted on 15 Dec 2016 |
|
US medical device maker Hologic, Inc. (Bedford, MA, USA) has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA (Barcelona, Spain), for USD 1.85 billion in cash.
Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products. The company's core business units focus on diagnostics, breast health, gynecological surgery, and skeletal health. Since 1998, Hologic has worked with Grifol, which develops plasma protein therapies, to develop their blood-screening business.
The Procleix blood-screening business offers molecular assays and instruments to blood banks for screening donated blood, prior to transfusion, for viruses including HIV, hepatitis C and B, West Nile and Zika. Hologic handles research and development and manufacturing of the Procleix blood-screening products, while Grifols is responsible for selling the molecular assays and instruments.
As per the deal, which has been approved by boards of both the companies, Grifols will acquire Hologic's blood-screening manufacturing facility in Rancho Bernardo, California, as well as the development rights, licenses to patents and access to product manufacturers. Hologic will retain the engineering expertise associated with the blood-screening systems including Tigris and Panther, but will continue to work with Grifols to ensure that its customers have access to its blood-screening instruments over the long-term.
"Divesting our share of our blood screening business to Grifols will strengthen our efforts to build a sustainable growth company by accelerating top- and bottom-line growth rates, while significantly increasing financial flexibility," said Hologic’s chairman, president and CEO, Steve MacMillan. "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years. But at the same time, we believe that the business and our blood screening employees are best positioned to succeed under a single owner, and that this sale to Grifols provides excellent value for Hologic and our shareholders."
Related Links:
Hologic
Grifols
Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products. The company's core business units focus on diagnostics, breast health, gynecological surgery, and skeletal health. Since 1998, Hologic has worked with Grifol, which develops plasma protein therapies, to develop their blood-screening business.
The Procleix blood-screening business offers molecular assays and instruments to blood banks for screening donated blood, prior to transfusion, for viruses including HIV, hepatitis C and B, West Nile and Zika. Hologic handles research and development and manufacturing of the Procleix blood-screening products, while Grifols is responsible for selling the molecular assays and instruments.
As per the deal, which has been approved by boards of both the companies, Grifols will acquire Hologic's blood-screening manufacturing facility in Rancho Bernardo, California, as well as the development rights, licenses to patents and access to product manufacturers. Hologic will retain the engineering expertise associated with the blood-screening systems including Tigris and Panther, but will continue to work with Grifols to ensure that its customers have access to its blood-screening instruments over the long-term.
"Divesting our share of our blood screening business to Grifols will strengthen our efforts to build a sustainable growth company by accelerating top- and bottom-line growth rates, while significantly increasing financial flexibility," said Hologic’s chairman, president and CEO, Steve MacMillan. "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years. But at the same time, we believe that the business and our blood screening employees are best positioned to succeed under a single owner, and that this sale to Grifols provides excellent value for Hologic and our shareholders."
Related Links:
Hologic
Grifols
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Sample Transportation System
Tempus1800 Necto
Hemodynamic System Monitor
OptoMonitor
Latest Industry News
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
At-Home Blood Tests Accurately Detect Key Alzheimer's Biomarkers
Diagnosing Alzheimer’s disease typically relies on brain scans or spinal fluid tests, which are invasive, costly, and difficult to access outside specialist clinics. These barriers have limited large-scale... Read more
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read more
Ultra-Sensitive Blood Biomarkers Enable Population-Scale Insights into Alzheimer’s Pathology
Accurately estimating how many people carry Alzheimer’s disease pathology has long been a challenge, as traditional methods rely on small, clinic-based samples rather than the general population.... Read more
Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. While some patients live with few or no symptoms, others develop heart failure,... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
Urine drug testing plays a critical role in the emergency department, particularly for patients presenting with suspected overdose or altered mental status. Accurate and timely results can directly influence... Read more
New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
Ovarian cancer affects around one in 50 women during their lifetime, with roughly 7,000 diagnoses each year in the UK. The disease is often detected late because symptoms such as bloating, abdominal pain,... Read more
Technology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
